Market Access Updating of England’s budget impact test threshold England has a lot of ways to put downward pressure on prices of new treatments and the budget impact test - prompting commercial discussions if a new treatment looks like it will cost more
R&D The post-Covid New Normal: a golden opportunity for the NHS? I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis UK pharma denied legal challenge to drugs bill cap - updated Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Views & Analysis Improved access? The reality of the PPRS Keeping the UK branded medicines bill within affordable limits - has PPRS delivered?
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends